Step Pharma
Pre-clinicalOur lead asset, dencatistat (STP938), is a first-in-class, highly selective, orally bioavailable, targeted oncology therapy that aims to become a key drug for a multitude of cancer treatment regimens.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $95M
About
Our lead asset, dencatistat (STP938), is a first-in-class, highly selective, orally bioavailable, targeted oncology therapy that aims to become a key drug for a multitude of cancer treatment regimens.
Small Molecules
Funding History
2Total raised:$95M
Series B$67MJun 15, 2021
Series A$28MJun 15, 2018